Evidence method
Level · gp.fundamentals.capex_revenue_ratio
208.13% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CRNX · Mar 31, 2024
Crinetics Pharmaceuticals, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-24-057150General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-8258.75% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-76.11% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-11488.91% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
8334.53% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
2102.19% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History14 statesSelf-history eligible
Sep 30, 20190/6 normalizedLevel 3Dec 31, 20190/6 normalizedLevel 3Mar 31, 20200/6 normalizedLevel 3Dec 31, 20200/6 normalizedLevel 3Mar 31, 20235/6 normalizedLevel 3Jun 30, 20236/6 normalizedLevel 3Sep 30, 20236/6 normalizedLevel 3Mar 31, 20246/6 normalizedLevel 3Jun 30, 20246/6 normalizedLevel 3Mar 31, 20256/6 normalizedLevel 3Jun 30, 20256/6 normalizedLevel 3Dec 31, 20256/8 normalizedLevel 3Mar 31, 20266/8 normalizedLevel 3Jun 30, 20266/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 1011.56%
- Current
- 208.13%
- Delta
- -803.44%
- Previous
- -11947.69%
- Current
- -8258.75%
- Delta
- 3688.94%
- Previous
- -24.45%
- Current
- -76.11%
- Delta
- -51.66%
- Previous
- -17045.38%
- Current
- -11488.91%
- Delta
- 5556.47%
- Previous
- 12670.23%
- Current
- 8334.53%
- Delta
- -4335.70%
- Previous
- 3193.35%
- Current
- 2102.19%
- Delta
- -1091.17%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · CRNX Fundamental State →Analogous To · CRNX state analogue 4 →Transitioned To · CRNX Fundamental State →Transitioned To · CRNX CAPEX_INTENSITY_DECREASED →Transitioned To · CRNX CASH_GENERATION_INCREASED →Transitioned To · CRNX GROWTH_DECREASED →Transitioned To · CRNX PROFITABILITY_INCREASED →Transitioned To · CRNX R_AND_D_INTENSITY_DECREASED →Transitioned To · CRNX SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.